GlassScriptPhysician profile
Michael A Tolino
NPI 1932100930
$10,221.95
in general payments reported to CMS, 2019-2025
32 companies · $3,071 in 2025
The $3,071 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $132 · 2021: $847 · 2022: $1,756 · 2023: $2,210 · 2024: $2,107 · 2025: $3,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,194 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,193.74 |
| Education | $193.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,095.31 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,035.09 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $1,476.28 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,375.39 | 2021-2025 | Dupixent |
| Amgen INC. | $564.73 | 2022-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $362.53 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.00 | 2020-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Grifols USA, LLC | $285.60 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Insmed, INC. | $271.95 | 2022-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $250.76 | 2021-2025 | Glassia |
| Zoll Respicardia, INC. | $131.02 | 2023 | Remede System |
| Novartis Pharmaceuticals Corporation | $124.44 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $120.70 | 2022-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $114.92 | 2021-2025 | Winrevair, Keytruda |
| Baxter Healthcare | $85.91 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $73.17 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $65.73 | 2025 | Inspire |
| Vifor Pharma, INC. | $56.67 | 2024-2025 | Zemaira |
| Mylan Specialty L.P. | $56.60 | 2022-2023 | Yupelri |
| Pfizer INC. | $46.97 | 2023-2024 | |
| Electromed, INC. | $42.57 | 2022-2023 | Smartvest |
| Lilly USA, LLC | $36.36 | 2025 | Zepbound |
| Pulmonx Corporation | $31.39 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Paratek Pharmaceuticals, INC. | $28.92 | 2023 | Nuzyra |
| Viatris Specialty LLC | $28.28 | 2025 | Yupelri |
| Resmed Corp | $24.09 | 2024 | |
| Harmony Biosciences LLC | $22.51 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.62 | 2022 | |
| Gilead Sciences, INC. | $20.69 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.63 | 2021 | |
| Biomerieux INC | $15.28 | 2021 | |
| Foundation Medicine, INC. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tolino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.